Navigation Links
ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
Date:1/11/2010

MENLO PARK, Calif., Jan. 11 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Residual Protein A Detection Kit for use on the company's Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with unprecedented speed and minimal hands-on time. The company also announced the introduction of its Sidekick Offline Biosensor Immobilization Station, which enables offline loading of reagents on biosensors, in tandem with any Octet instrument, for enhanced efficiency and assay performance.

The Dip and Read Residual Protein A Detection Kit consists of biosensors and all the reagents required to quantitate Protein A or biosimilars such as MabSelect SuRe(TM), in the presence of human IgG.

"Protein A detection is a critical quality control step during drug development and manufacturing, but traditional methods are labor-intensive, complicated and time-consuming," said Christopher Silva, ForteBio's vice president of marketing. "Our new Dip and Read Residual Protein A Detection Kit offers the same sensitivity levels as existing methods, but requires significantly less hands-on time and can be completed in half the time."

The new Sidekick Offline Biosensor Immobilization Station works alongside any Octet instrument and enables offline, simultaneous and uniform sample loading on all 96 biosensors on a biosensor tray. This increases efficiency by freeing up the Octet system for other uses. Additionally, the instrument shakes the samples, while keeping the biosensors immobile, which decreases the required incubation time by one half, thereby doubling the biosensor preparation productivity. Further, for sandwich assays, this process significantly increases the assay's sensitivity.

"Our Sidekick instrument enables more samples to be run in significantly less time and with greater assay performance. It is ideal for rapid custom biosensor batch preparation and multistep Octet sandwich assays, which are used to detect impurities - such as residual Protein A in therapeutic antibody products," said Mr. Silva.

ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.


    CONTACT:
    Gemma Milan 650-289-6800
    gmilan@fortebio.com

SOURCE ForteBio, Inc.

RELATED LINKS
http://www.fortebio.com

'/>"/>

SOURCE ForteBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CDC Foundation Launches Viral Hepatitis Action Coalition
2. URL Pharma Launches Colcrys(R) Patient Assistance Program
3. URL Pharma Launches Co-Pay Assistance Program for Colcrys(R)
4. CPG International Launches a New Generation of VYCOM
5. DecisionView Launches StudyOptimizer(TM) 4
6. The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicares Power Mobility Benefit
7. FDA Launches Orphan Drug Workshop at KGI
8. Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture
9. New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
10. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
11. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, ... of a class action lawsuit on behalf of purchasers ... KTOV ) pursuant and/or traceable to Kitov,s initial public ... and/or on the open market from November 20, 2015 ... Period"). The lawsuit seeks to recover damages for Kitov ...
(Date:3/28/2017)... 2017 Summary ... as a Key Component of Multichannel Marketing" provides ... landscape in the digital age. While the ... medical advancements, it has been much slower to ... on traditional channels and methods. However, the decreasing ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... treatment of a growing number of cancers and is touted to be the next ... of treatment, thus far, has been in the form of immune checkpoint inhibitors such ...
(Date:3/29/2017)... Richmond, VA (PRWEB) , ... March 29, 2017 , ... ... of its seventh North American office location in Richmond, Virginia, located at the Riverfront ... April 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of ...
(Date:3/28/2017)... YORK, NEW YORK (PRWEB) , ... March 28, ... ... breakthrough development, NTX Technology™, is the first technology to directly address the resolution ... Health Organization. NTX Technology™ is a patented compound of FDA and TTB approved ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the ... titled The Thyroid Secret. Dr. Wentz talked about journey and research recently on a ... medication IS NOT the only solution to deal with thyroid disease. , Dr. ...
Breaking Medicine News(10 mins):